UC Davis

The company published data from a 1,102-patient trial that found that amino acid markers could be useful for diagnosing the condition in a subset of patients.

Researchers showed, retrospectively, that using a cutoff of 16 circulating DNA mutations they could identify patients who were more likely to respond to immunotherapy.